Bristol-Myers Squibb

4Q Revenues: $5.2 billion (+22%)

4Q Earnings: $894 million (loss of $197 million 4Q15)

FY Revenues: $19.4 billion (+17%)

FY Earnings: $4.5 billion (earnings were $1.6 billion FY15)

Comments: Growth was driven by key products, Opdivo, with $3.8 billion in sales, up from $942 million FY15, and Eliquis, with sales of $3.3 billion, up 80%. Sprycel sales were up 13% to $1.8 billion. Yervoy sales were down 6% to $1.1 billion. Virology sales slipped for the company’s four franchises. The hepatitis C franchise sales were down 51% to $226 million due to competing products from Gilead and AbbVie. HIV franchises for Sustiva and Reyataz were down 21% and 24% to $246 million and $206 million, respectively, and hepatitis B drug Baraclude sales were down 4% to $296 million.